Indian Diabetes Market Overview 2018: Growth, Demand and Forecast Research Report to 2023

1
    Indian Diabetes Market to Grow at 16.9
During 2018-2023

Copyright IMARC. All Rights Reserved
2
About IMARC Group
Report Description
IMARC is a leading advisor on management
strategy and market research worldwide. We
partner with clients in all sectors and regions
to identify their highest-value opportunities,
address their most critical challenges, and
transform their businesses. IMARCs information
products include major market, scientific,
economic and technological developments for
business leaders in pharmaceutical, industrial,
and high technology organizations. Market
forecasts and industry analysis for
biotechnology, advanced materials,
pharmaceuticals, food and beverage, travel and
tourism, nanotechnology and novel processing
methods are at the top of the companys
expertise. IMARCs tailored approach combines
unfathomable insight into the dynamics of
companies and markets with close cooperation at
all levels of the client organization. This
ensures that our clients achieve unmatchable
competitive advantage, build more proficient
organizations, and secure lasting results.
3
Report Description and Highlights
Report Description
  Indian Diabetes Market to Grow at 16.9 During
2018-2023 The Indian diabetes market has
experienced a robust growth over the past few
years. This can be attributed to the growing
awareness among consumers about the negative
health effects of diabetes coupled with
developing healthcare infrastructure in the
country. According to the latest report by IMARC
Group, titled Indian Diabetes Market Industry
Trends, Share, Size, Growth, Opportunity and
Forecast 2018-2023, the Indian diabetes
market reached a value of US 1,665 Million in
2017. Diabetes is a chronic disease caused by
improper production of or response to insulin in
the body which causes high blood sugar levels.
Uncontrolled diabetes can result in a variety of
complications, such as visual, cardiovascular,
renal and neural disorders.
4
Report Description and Highlights
Report Description
The heightening obesity rates, rising stress
levels and lack of proper exercise are the major
causes of diabetes in India. In order to control
the damage caused by the increasing cases of
diabetes in the country, the Indian Government is
taking initiatives to provide free treatment and
insulin to diabetics at government
hospitals. The growing awareness among the
consumers regarding the symptoms of diabetes and
its adverse health effects have largely
intensified the diagnosis and drug treatment
rates in the country. This is the major
growth-driving factor for the diabetes market in
India. Some of the other factors contributing to
the market growth are rapid urbanisation,
developing healthcare infrastructure, low-cost of
drug production, accelerating pharmaceutical
contract manufacturing and introduction of
advanced technologies. However, high research and
development costs, stringent pricing policy,
technological developments that make the existing
drugs unmarketable or obsolete, and regulatory
approvals in terms of quality control, price
control and IPR (Intellectual Property Rights)
protection are the major factors hampering the
market growth. Looking forward, the market value
is projected to exceed US 4,261 Million by 2023,
expanding at a CAGR of 16.9 during
2018-2023. Read more here https//www.imarcgroup
.com/india-diabetes
5
Report Description and Highlights
Report Description

•  
• Market Summary
• On the basis of type, the market has been
  segmented into type-1 and type-2 diabetes.
  Currently, type-2 diabetes accounts for the
  maximum share.
• On the basis of region, the market has been
  segregated into urban and rural regions. The
  prevalence of diabetes in the urban population is
  much higher as opposed to the rural areas.
• Based on gender, the market has been classified
  into males and females. Amongst these, the
  prevalence of diabetes in males is higher in
  comparison with females.
• On the basis of age group, age group of 40-59
  years holds the largest share of the diabetes
  population in India. It is followed by age group
  of 60-79 years and 20-39 years.
• The competitive landscape of the market has also
  been examined with some of the key players being
  Novo Nordisk, Sanofi Aventis, Eli Lilly, Biocon
  and Wockhardt.
• Want more information about this market? Request
  a free report sample
• https//www.imarcgroup.com/request?typereportid
  550flagB

6
Report Description and Highlights
Report Description
  Browse Related Report United States Diabetes
Market Report https//www.imarcgroup.com/us-diabe
tes-market Canada Diabetes Market Report
https//www.imarcgroup.com/canada-diabetes-market

7
Report Description and Highlights
Report Description

2017 IMARC All Rights Reserved This
Publication and all its contents unless
otherwise mentioned are copyrighted in the name
of International Market Analysis Research and
Consulting (IMARC). No part of this publication
may be reproduced, repackaged, redistributed or
resold in whole or in any part. The publication
may also not be used in any form or by and means
graphic electronic or mechanical, including
photocopying, recording, taping or by information
storage or retrieval, or by any other form,
without the express consent of International
Market Analysis Research and Consulting
(IMARC). Disclaimer All contents and data of
this publication, including forecasts, data
analysis and opinion have been based on
information and sources believed to be accurate
and reliable at the time of publishing.
International Market Analysis Research and
Consulting makes no representation of warranty of
any kind as to the accuracy or completeness of
any Information provided. IMARC accepts no
liability whatsoever for any loss or damage
resulting from opinion, errors or inaccuracies if
any found this publication. IMARC, IMARC Group
and Global Therapy Insight Series are registered
trademarks of International Market Analysis
Research and Consulting. All other trademarks
used in this publication are registered
trademarks of their respective companies.
8

Contact Us